Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Adolescent
Adult
Antimalarials
/ administration & dosage
Artemisinins
/ administration & dosage
Child
Child, Preschool
Chloroquine
/ administration & dosage
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Infant
Malaria, Vivax
/ drug therapy
Male
Middle Aged
Myanmar
Primaquine
/ administration & dosage
Quinolines
/ administration & dosage
Recurrence
Thailand
Young Adult
Plasmodium vivax
chloroquine
dihydroartemisinin-piperaquine
primaquine
radical cure
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
08 04 2019
08 04 2019
Historique:
received:
08
08
2018
accepted:
23
08
2018
pubmed:
6
4
2019
medline:
26
6
2020
entrez:
6
4
2019
Statut:
ppublish
Résumé
Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain. A randomized controlled trial was performed to compare the tolerability and radical curative efficacy of 7-day versus 14-day high-dose primaquine regimens (total dose 7mg/kg) with either chloroquine or dihydroartemisinin-piperaquine. Patients with uncomplicated P. vivax malaria on the Thailand-Myanmar border were randomized to either chloroquine (25mg base/kg) or dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine, either 0.5 mg/kg/day for 14 days or 1 mg/kg/day for 7 days. Adverse events within 42 days and 1-year recurrence rates were compared and their relationship with day 6 drug concentrations assessed. Between February 2012 and July 2014, 680 patients were enrolled. P. vivax recurrences (all after day 35) occurred in 80/654 (12%) patients; there was no difference between treatments. Compared to the 7-day primaquine groups the pooled relative risk of recurrence in the 14-day groups was 1.15 (95% confidence interval 0.7 to 1.8). Hematocrit reductions were clinically insignificant except in G6PD female heterozygotes, 2 of whom had hematocrit reductions to <23% requiring blood transfusion. Radical cure should be deployed more widely. The radical curative efficacy in vivax malaria of 7-day high-dose primaquine is similar to the standard 14-day high-dose regimen. Chloroquine and dihydroartemisinin-piperaquine are both highly effective treatments of the blood stage infection. Quantitative point of care G6PD testing would ensure safe use of the 7-day high-dose primaquine regimen in G6PD heterozygous females. NCT01640574.
Sections du résumé
BACKGROUND
Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain. A randomized controlled trial was performed to compare the tolerability and radical curative efficacy of 7-day versus 14-day high-dose primaquine regimens (total dose 7mg/kg) with either chloroquine or dihydroartemisinin-piperaquine.
METHODS
Patients with uncomplicated P. vivax malaria on the Thailand-Myanmar border were randomized to either chloroquine (25mg base/kg) or dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine, either 0.5 mg/kg/day for 14 days or 1 mg/kg/day for 7 days. Adverse events within 42 days and 1-year recurrence rates were compared and their relationship with day 6 drug concentrations assessed.
RESULTS
Between February 2012 and July 2014, 680 patients were enrolled. P. vivax recurrences (all after day 35) occurred in 80/654 (12%) patients; there was no difference between treatments. Compared to the 7-day primaquine groups the pooled relative risk of recurrence in the 14-day groups was 1.15 (95% confidence interval 0.7 to 1.8). Hematocrit reductions were clinically insignificant except in G6PD female heterozygotes, 2 of whom had hematocrit reductions to <23% requiring blood transfusion.
CONCLUSION
Radical cure should be deployed more widely. The radical curative efficacy in vivax malaria of 7-day high-dose primaquine is similar to the standard 14-day high-dose regimen. Chloroquine and dihydroartemisinin-piperaquine are both highly effective treatments of the blood stage infection. Quantitative point of care G6PD testing would ensure safe use of the 7-day high-dose primaquine regimen in G6PD heterozygous females.
CLINICAL TRIALS REGISTRATION
NCT01640574.
Identifiants
pubmed: 30952158
pii: 5079011
doi: 10.1093/cid/ciy735
pmc: PMC6452005
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Quinolines
0
artenimol
6A9O50735X
Chloroquine
886U3H6UFF
piperaquine
A0HV2Q956Y
Primaquine
MVR3634GX1
Banques de données
ClinicalTrials.gov
['NCT01640574']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1311-1319Subventions
Organisme : Wellcome Trust
ID : 089179/Z/09/Z
Pays : United Kingdom
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Blood. 1968 Nov;32(5):816-8
pubmed: 4386875
Antimicrob Agents Chemother. 2007 Nov;51(11):4090-7
pubmed: 17846129
PLoS Med. 2013;10(3):e1001398
pubmed: 23472056
Am J Trop Med Hyg. 1973 Nov;22(6):693-5
pubmed: 4583162
Indian J Med Res. 1977 May;65(5):652-6
pubmed: 336529
Trans R Soc Trop Med Hyg. 1998 May-Jun;92(3):341
pubmed: 9861412
J Health Popul Nutr. 2009 Feb;27(1):4-13
pubmed: 19248643
Acta Trop. 2004 Feb;89(3):351-6
pubmed: 14744561
Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):433-8
pubmed: 10674098
Clin Infect Dis. 2011 Nov;53(10):977-84
pubmed: 22002979
Am J Trop Med Hyg. 2008 May;78(5):736-40
pubmed: 18458306
BMC Med. 2015 Dec 11;13:294
pubmed: 26654101
Malar J. 2010 Nov 01;9:308
pubmed: 21040545
J Infect Dis. 2012 Dec 1;206(11):1771-80
pubmed: 22966124
Am J Trop Med Hyg. 2010 Apr;82(4):542-7
pubmed: 20348496
Am J Trop Med Hyg. 2010 Jun;82(6):1017-23
pubmed: 20519594
Lancet. 2014 Mar 22;383(9922):1049-58
pubmed: 24360369
Adv Parasitol. 2012;80:1-111
pubmed: 23199486
Am J Trop Med Hyg. 1997 Jun;56(6):627-31
pubmed: 9230793
Trials. 2011 May 03;12:106
pubmed: 21539749
Am J Trop Med Hyg. 1977 May;26(3):562-3
pubmed: 326072
Ann Trop Med Parasitol. 1999 Dec;93(8):809-12
pubmed: 10715673
Southeast Asian J Trop Med Public Health. 2011 Jan;42(1):9-18
pubmed: 21323159
PLoS Med. 2017 Feb 7;14(2):e1002224
pubmed: 28170391
Int J Parasitol Drugs Drug Resist. 2017 Aug;7(2):181-190
pubmed: 28384505
JAMA. 2006 Mar 8;295(10):1152-60
pubmed: 16522836
J Infect Dis. 1994 Apr;169(4):932-5
pubmed: 8133114
BMC Infect Dis. 2015 Dec 07;15:558
pubmed: 26643116
Clin Infect Dis. 2018 Oct 30;67(10):1543-1549
pubmed: 29889239
Trans R Soc Trop Med Hyg. 2011 Oct;105(10):568-73
pubmed: 21890160